<p>Meta-analysis of the reported systemic adverse events observed in non-health subjects receiving saponin-adjuvanted vaccines or placebo.</p
<p>Meta-analysis of fatal cardiovascular events in RCTs (FEV1≥50%) of LABAs compared with placebo.</...
<p>Meta-analysis of the logs hazard ratios of overall survival comparing bevacizumab and standard th...
<p>Meta-analysis of fatal CVD events in populations with varying degrees of control for CVD status a...
<p>Meta-analysis of the reported local adverse events observed in non-healthy subjects receiving ISC...
<p>Meta-analysis of the reported local adverse events observed in non-healthy subjects receiving QS-...
<p>Meta-analysis of the toxicities in patients with cancer randomly assigned to celecoxib or placebo...
<p>Meta-analysis of adverse events rate ratio comparisons in controls and disulfiram treated patient...
<p>Meta-analysis of fatal cardiovascular events in RCTs of LABAs compare with placebo.</p
<p>Meta-analysis of non-fatal CVD events in unselected populations with varying degrees of control f...
<p>Meta-analysis of fatal cardiovascular events in short-term RCTs of LABAs compared with placebo.</...
<p>Meta-analysis of the withdrawal rate of the rotigotine and placebo-treated groups.</p
<p>Meta-analysis of fatal cardiovascular events in long-term RCTs of LABAs compared with placebo.</p
<p>Meta-analysis of fatal cardiovascular events in RCTs (FEV1<50%) of LABAs compared with placebo.</...
Adverse events following the use of medical interventions are a major source of concern for patients...
<p>Subgroup analysis of patients treated with different doses of pembrolizumab revealed a dose-depen...
<p>Meta-analysis of fatal cardiovascular events in RCTs (FEV1≥50%) of LABAs compared with placebo.</...
<p>Meta-analysis of the logs hazard ratios of overall survival comparing bevacizumab and standard th...
<p>Meta-analysis of fatal CVD events in populations with varying degrees of control for CVD status a...
<p>Meta-analysis of the reported local adverse events observed in non-healthy subjects receiving ISC...
<p>Meta-analysis of the reported local adverse events observed in non-healthy subjects receiving QS-...
<p>Meta-analysis of the toxicities in patients with cancer randomly assigned to celecoxib or placebo...
<p>Meta-analysis of adverse events rate ratio comparisons in controls and disulfiram treated patient...
<p>Meta-analysis of fatal cardiovascular events in RCTs of LABAs compare with placebo.</p
<p>Meta-analysis of non-fatal CVD events in unselected populations with varying degrees of control f...
<p>Meta-analysis of fatal cardiovascular events in short-term RCTs of LABAs compared with placebo.</...
<p>Meta-analysis of the withdrawal rate of the rotigotine and placebo-treated groups.</p
<p>Meta-analysis of fatal cardiovascular events in long-term RCTs of LABAs compared with placebo.</p
<p>Meta-analysis of fatal cardiovascular events in RCTs (FEV1<50%) of LABAs compared with placebo.</...
Adverse events following the use of medical interventions are a major source of concern for patients...
<p>Subgroup analysis of patients treated with different doses of pembrolizumab revealed a dose-depen...
<p>Meta-analysis of fatal cardiovascular events in RCTs (FEV1≥50%) of LABAs compared with placebo.</...
<p>Meta-analysis of the logs hazard ratios of overall survival comparing bevacizumab and standard th...
<p>Meta-analysis of fatal CVD events in populations with varying degrees of control for CVD status a...
DOI
Add to ORKG